



Synairgen plc

(‘Synairgen’ or the ‘Company’)

Result of General Meeting

Further to Synairgen’s announcement of 25 September 2018, the Company is pleased to announce today the passing of the Resolutions at the General Meeting held earlier today. The Placing and Subscription remain conditional on Admission of the New Ordinary Shares to AIM, which is expected to take place at 8.00 a.m. on Monday 15 October 2018.

With effect from Admission, the Company will have 109,433,442 Ordinary Shares in issue, with no shares held in treasury. Shareholders may use this figure as the denominator by which they are required to notify their interest in, or change to their interest in, the Company under the Disclosure Guidance and Transparency Rules.

Following Admission, the shareholdings of the below Directors of the Company, who participated in the Fundraise, are as follows:

<i>Director</i>	Ordinary Shares held prior to the Fundraise	Ordinary Shares subscribed for in the Fundraise	Ordinary Shares held after the Fundraise	Percentage of the Enlarged Issued Share Capital held
Richard Marsden	154,432	156,250	310,682	0.28%
Dr Phillip Monk	183,439	46,875	230,314	0.21%
John Ward	276,506	62,500	339,006	0.31%

Capitalised terms in the text of this announcement have the meanings given to them in the Company's circular dated 26 September 2018.

For further enquiries, please contact:

Synairgen plc

Richard Marsden, Chief Executive Officer

John Ward, Finance Director

Tel: + 44 (0) 23 8051 2800

finnCap

Geoff Nash, Max Bullen-Smith (Corporate Finance)

Alice Lane (ECM)

Tel: + 44 (0) 20 7220 0500

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott / Sukaina Virji / Laura Thornton

synairgen@consilium-comms.com

Tel: +44 (0) 20 3709 5701

Notes for Editors

About Synairgen

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Leveraging its scientific and clinical facilities at Southampton General Hospital, the Company uses *in vitro* and *ex vivo* models to progress opportunities into clinical development. The BioBank of human samples is used in these models to increase confidence in the likelihood of successful drug development.

Synairgen is currently running a two-part Phase II trial evaluating SNG001, the Company's wholly-owned inhaled interferon beta (IFN-beta) therapeutic candidate. The Phase II trial, called SG015, has been designed to assess the safety of SNG001 in COPD patients and its clinical benefit in these patients when they have a cold or flu infection, a major driver of COPD exacerbations.

Core to Synairgen's business strategy is the realisation of value via licensing transactions. In August 2015 the Company entered into a collaboration with Pharmaxis to develop an oral LOXL2 inhibitor to reduce fibrosis in patients with idiopathic pulmonary fibrosis (IPF). In December 2017 the collaboration agreement was amended as Pharmaxis took on full responsibility for the programme, with Synairgen receiving a £5 million upfront payment and circa 17% of any future net partnering proceeds from all fibrotic indications.

Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Richard Marsden
2.	Reason for the Notification	
a)	Position/status	PDMR – CEO
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	Synairgen plc
b)	LEI	213800IMMTOPPDF8HD24
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	

a)	Description of the Financial instrument, type of instrument Identification code	Ordinary Shares of 1 p each GB00B0381Z20	
b)	Nature of the transaction	Purchase of Ordinary Shares	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		16 pence	156,250
d)	Aggregated information: <ul style="list-style-type: none"> Aggregated volume Price 	N/A, single transaction as per 4c above	
e)	Date of the transaction	12 October 2018	
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)	

1.	Details of the person discharging managerial responsibilities / person closely associated		
a)	Name	Dr. Phillip Monk	
2.	Reason for the Notification		
a)	Position/status	PDMR – Chief Scientific Officer	
b)	Initial notification/Amendment	Initial notification	
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	Synairgen plc	
b)	LEI	213800IMMTOPPDF8HD24	
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the Financial instrument, type of instrument Identification code	Ordinary Shares of 1 p each GB00B0381Z20	
b)	Nature of the transaction	Purchase of Ordinary Shares	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		16 pence	46,875
d)	Aggregated information: <ul style="list-style-type: none"> Aggregated volume Price 	N/A, single transaction as per 4c above	
e)	Date of the transaction	12 October 2018	
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)	

1.	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	John Ward

2.	Reason for the Notification		
a)	Position/status	PDMR – Finance Director	
b)	Initial notification/Amendment	Initial notification	
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	Synairgen plc	
b)	LEI	213800IMMTOPPDF8HD24	
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the Financial instrument, type of instrument Identification code	Ordinary Shares of 1 p each GB00B0381Z20	
b)	Nature of the transaction	Purchase of Ordinary Shares	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		16 pence	62,500
d)	Aggregated information: <ul style="list-style-type: none"> • Aggregated volume • Price 	N/A, single transaction as per 4c above	
e)	Date of the transaction	12 October 2018	
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)	